Podcasts about stop tb partnership

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test, published by Gemma Paterson on September 12, 2023 on The Effective Altruism Forum. Really great piece from Good Good Good on the campaign to pressure Danaher to reduce the price of their TB test. Excited to see the outcome! Tuberculosis is the world's deadliest disease - and it is entirely curable. The airborne disease has plagued human history, and the World Health Organization estimates that 10 million people across the globe are infected by TB every year. Of those millions, 1.6 million still die each year, despite the existence of life-saving technology and medicine. These are facts that enrage many - but especially author and philanthropist John Green. "Why am I passionate about TB? It's the deadliest disease in human history, but for most of human history we couldn't do much about it. However, since the mid-1950s, TB has been curable - yet we still allow TB to kill over 1.6 million people per year," Green told Good Good Good. "This is horrifying to me. I don't want to accept a world where we know how to cure Tuberculosis but deny millions of people access to that cure." This passion was put on display in July of this year. Through the social media campaign #PatientsNotPatents, Green and his fanbase - called Nerdfighters, or Nerdfighteria in collective form - followed the lead of TB advocates to call on drug company Johnson & Johnson to allow the sale of generic bedaquiline - a life-saving TB drug that had been inaccessible under the company's patent for over a decade. Nerdfighteria - as well as longtime TB organizations such as the Stop TB Partnership and TB-survivors Phumeza Tisile and Nandita Venkatesan - was successful, and Johnson & Johnson ended its reign on bedaquiline (though advocates are still working to ensure that all low- and middle-income countries receive access to the generic drug). To end the TB epidemic by 2030 - a goal shared by both the WHO and the United Nations - more pharmaceutical companies need to do their part to make healthcare more accessible, especially in countries with a high TB burden. So, in their effort to end TB, Nerdfighteria has taken on a new company: Danaher. The Issue Danaher is a multinational corporation, founded by brothers Steven and Mitchell Rales, that owns a number of other large companies, such as Cepheid, Pantone, and X-Rite. (Steven Rales also founded Indian Paintbrush Films, which has financed many of Wes Anderson's movies.) Most relevant to this campaign, however, is that in 2006, Danaher and molecular diagnostics company Cepheid created the most helpful diagnostic resource for TB: The GeneXpert machine. This rapid molecular testing machine is able to test for a number of infectious diseases, including COVID, HIV, TB, and multidrug-resistant TB. In fact, the WHO recommends Xpert tests as the initial test for all people with signs and symptoms of TB. The GeneXpert machine itself is cost-effective, but its testing cartridges are more costly. The company charges about $10 per regular TB testing cartridge and about $15 per multidrug-resistant TB testing cartridge (though both tests cost the same to manufacture). According to a 2019 brief from Doctors Without Borders, Danaher and Cepheid could reduce the cost of these cartridges to just $5 each - or lower - based on continuous increases in volume. The brief said a "20-30% reduction in price may be overdue" thanks to expansion in volume. "These pricing packages serve to expand Cepheid's footprint . and do nothing to address the urgent need to scale up affordable testing for COVID-19, TB, and other diseases, or to address the longstanding lack of affordability and unfair pricing of Xpert tests," David Branigan, of activist organization Treatment Action Group, said in a statement in 2...

This Podcast features Peter Ngo'la Owiti, who is on the Executive Committee Board of Stop TB Partnership, and also represents communities on Medicines Patent Pool. He is also the Executive Director of the Wote Youth Development Projects, Kenya. Listen to his insights on why stock-outs of medicines for drug-sensitive TB, essential needs which are required to refer patients, or of cartridges to run nucleic acid amplification tests (NAAT) molecular diagnostics such as Gene Xpert are not acceptable.Listen to this podcast on Apple Podcasts, Amazon Music, Google Podcasts, Spotify, Stitcher, TuneIn, aCast, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, Player FM, and other podcast streaming platforms.ThanksCNS team

In this episode we chat to renowned epidemiologist, healthcare innovator, and educator Dr. Richard Garfein and social entrepreneur and infectious disease epidemiologist Dr. Kelly Collins, as they share their journey of turning an idea from research in academia into a successful commercial enterprise. They discuss their experiences in starting SureAdhere, licensing the software from UCSD, and signing up health departments to use the technology. You'll also hear about their work in using Video Directly Observed therapy (VDOT) to transform tuberculosis (TB) treatment, and how they expanded their company's reach to cover diseases from hepatitis C to opioid use disorder. The episode highlights the importance of following evidence-based decision-making and empowering patients and healthcare workers alike by leveraging technology, innovation, and passion. Topics include: The development of Video Directly Observed Therapy (VDOT) technology The role of DOT and VDOT in healthcare interventions Telemedicine during COVID-19 and beyond Digital technology to support medication assisted treatment and opioid use disorder-The importance of evidence-based decision-making in developing and testing technology The decision to start a company to scale VDOT technology and make it more widely available The challenges of licensing the software from UCSD and signing up health departments to use the technology The impact of VDOT on improving patient experiences and healthcare provider efficiency. Lessons learned from the experience of starting and growing SureAdhere The decision to join forces with Dimagi Related Resources: SureAdhere: https://www.sureadhere.com / The Stop TB Partnership: https://www.stoptb.org  The UK National Health Service: https://www.nhs.uk  The Centers for Disease Control and Prevention: https://www.cdc.gov   Verizon Foundation: https://www.verizon.com/about/responsibility/grant-requirements Sign up to our newsletter, and stay informed of Dimagi's work :⁠⁠⁠⁠https://sites.dimagi.com/newsletter-sign-up⁠⁠⁠⁠  We are on social media - follow us for the latest from Dimagi: LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/dimagi⁠⁠⁠⁠ Twitter:⁠⁠⁠⁠https://twitter.com/dimagi/⁠⁠⁠⁠ Facebook:⁠⁠⁠⁠https://www.facebook.com/dimagi.inc/⁠⁠⁠⁠ Youtube:⁠⁠⁠⁠https://www.youtube.com/channel/UCt8JcRhWywkVJRR_YWv4OhA⁠⁠⁠⁠  If you enjoy this show, please leave us a 5-Star Review and share your favorite episodes with friends. Hosts: Jonathan Jackson: ⁠⁠⁠⁠https://www.linkedin.com/in/jonathanljackson/⁠⁠⁠⁠ Amie Vaccaro: ⁠⁠⁠⁠https://www.linkedin.com/in/amievaccaro/ ⁠⁠⁠

The second leading cause of death from infectious disease around the world is Tuberculosis, following COVID. 10 million people globally develop TB each year, and in 2021 1.6 million died from Tuberculosis.  So why is a disease that is preventable and curable still inflicting such a major toll on the health and welfare of so many people and what can be done to reduce the burden of TB around the world? Joining me to answer these questions and more is Dr. Lucica Ditiu, executive director of the Stop TB Partnership.  We kick off discussing trends in TB around the world including how covid impacted efforts to reach global targets around reducing sickness and death from TB. We then have a longer conversation about what can be done to accelerate progress against this deadly disease.     

Pop stars are often involved in raising the visibility of public health issues. Elton John is one obvious example for his work on HIV/AIDS. Rarely, though are pop-stars involved in gathering public health stats. Ugandan pop star Bebe Cool is the exception and his work to combat tuberculosis is a focus of this episode of Stats and Stories. Sandra Alba is an epidemiologist at KIT Royal Tropical Institute in Amsterdam. She trained as a medical statistician in the UK and soon after moved to Tanzania to complete a PhD program on access to malaria treatment. For the past 15 years, she has applied statistical and epidemiological methods to evaluate public health programs in low- and middle-income countries. Her research focuses on data quality and good epidemiological practice - specifically the interplay between research integrity and fairness in multi-disciplinary international research collaborations. Dr. Amera Khan is the Technical Officer at Stop TB Partnership in Switzerland whose goal is to reach TB-affected people and communities wherever they are to create innovative and new solutions for affected populations.

In a special 3-part season premiere, Halteres Presents is spotlighting tuberculosis diagnostics worldwide, and where things stand in the field today. In Part Three, Rich Thayer and Mickey Urdea are interviewing Dr. Shibu Vijayan, the Medical Director for Global Health Practice at Qure.ai, a healthtech company that uses artificial intelligence assistance for medical imaging diagnostics. Dr. Vijayan is a senior clinician in Community and Public Health Services with over 25 years of experience in developing, monitoring, and evaluating public health projects, including developing healthcare-related proposals in both private and not-for-profit organizations. He is also an accredited International general Tuberculosis (TB) expert by the TB team hosted by WHO and Stop TB Partnership. Prior to Qure.ai, Dr. Vijayan was at PATH and has also worked with the WHO as Technical Consultant for the TB Control Program in India and was associated with Medicines Sans Frontiers (MSF, Netherlands) as a field Epidemiologist in Ethiopia.

The pandemic shattered global efforts to control tuberculosis, which was the most lethal infectious disease in the world until covid-19 took its crown. Now, with deaths rising, TB is set to reclaim that dubious honour. But the covid era also holds important lessons for the fight against TB. Can innovations such as genomic sequencing facilities and new vaccine technologies be applied to TB care, too?Avantika Chilkoti, The Economist's international correspondent, travels to Rio de Janeiro in Brazil to find out why TB is a disease of the poor. Mel Spigelman of the TB Alliance and Lucica Ditiu of the Stop TB Partnership say tackling the disease is a question of political will. Josefina Campos of ANLIS in Argentina explains how genomic sequencing helps monitor TB drug resistance. Author Vidya Krishnan talks about TB's influence on art and culture. Plus, we examine why doctors are worried about the prospect of a new, highly contagious form of TB that doesn't respond to existing drugs. Alok Jha hosts.For full access to The Economist's print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

The pandemic shattered global efforts to control tuberculosis, which was the most lethal infectious disease in the world until covid-19 took its crown. Now, with deaths rising, TB is set to reclaim that dubious honour. But the covid era also holds important lessons for the fight against TB. Can innovations such as genomic sequencing facilities and new vaccine technologies be applied to TB care, too?Avantika Chilkoti, The Economist's international correspondent, travels to Rio de Janeiro in Brazil to find out why TB is a disease of the poor. Plus, Mel Spigelman of the TB Alliance and Lucica Ditiu of the Stop TB Partnership explain why tackling the disease is a question of political will. And, we examine why doctors are worried about the prospect of a new, highly contagious form of TB that doesn't respond to existing drugs. Alok Jha hosts.For full access to The Economist's print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Dr. Amera Khan, a technical officer at the Stop TB Partnership in Geneva, Switzerland, and Sarah Gregory discuss treatment of latent TB among US-bound immigrants in Vietnam.

Our guests Jacob Creswell from the https://www.stoptb.org/ (STOP TB Partnership) and Brenda Mungai from the Liverpool School of Tropical Medicine, provide insight into how technology is playing a key role in TB diagnosis, and highlights from the discussion include:  The technologies currently available to help diagnose TB  The role of artificial intelligence (AI) in TB diagnosis  The involvement of communities in the development of AI and the benefits that people are seeing from these developments  Dr. Jacob Creswell is Head of Innovations & Grants at the Stop TB Partnership. He coordinates the TB REACH initiative which is focused on improving programmatic aspects of tuberculosis case detection and treatment outcomes. He serves as a global expert on different aspects of improving tuberculosis case detection including private sector engagement and active case finding. Jacob is currently working on the introduction of new diagnostic and screening tools for TB including artificial intelligence and how they can fit into more efficient and effective diagnostic algorithms. Jacob has published more than 80 scientific publication and has over 20 years of experience working at Stop TB, WHO and CDC on TB and HIV.  https://www.lstmed.ac.uk/research/centres-and-units/impala/impala-team/brenda-mungai (Dr Brenda Nyambura Mungai)  PhD candidate, Liverpool School of Tropical Medicine, Director of Tuberculosis and Lung Health  Centre for Health Solutions-Kenya  A medical doctor Bachelor's degree of Medicine and Surgery (University of Nairobi) with a postgraduate diploma in HIV management (Colleges of Medicine South Africa) and a Masters in Tropical Medicine and Infectious Diseases (Liverpool, United Kingdom). She has over fifteen years national and international professional experience in clinical care and public health approaches to management of infectious diseases especially in TB/ HIV in developing countries. Currently pursuing a PhD in Global Health at Liverpool School of Tropical Medicine focusing on operational modelling, and the role of chest X-ray and computer-aided detection software in tuberculosis screening in low -and lower-middle income countries.  

As all eyes have been on the virus, other serious killer diseases took a backseat. Resources and staff were diverted, lockdowns were common all over the world and a very real fear of Covid-19 kept people away from clinics and hospitals. Claudia Hammond and her expert panel from Africa, Asia, Europe and Latin America look at the devastating impact of the pandemic on illnesses other than Covid, on global killers like tuberculosis, polio, measles and HIV/Aids. And they hear that the worldwide disruption to cancer care will inevitably lead to late diagnoses, late-stage cancer treatment and more deaths. Dr Ramya Ananthakrishnan runs REACH, which supports, cares for and organises treatment for TB patients in Chennai, India's fourth most populous city. She tells Claudia about how hard the pandemic hit the work they do. Claudia's guests include Dr Abeeba Kamarulzaman, Professor of Medicine and Infectious Diseases at the University of Malaya in Kuala Lumpur, Malaysia and the President of the International Aids Society; Dr Lucica Ditiu, respiratory physician originally from Romania, Executive Director of the Stop TB Partnership, Geneva, Switzerland; Dr Balcha Masresha, coordinator of the measles and rubella programmes for the World Health Organisation in Brazzaville, Congo and cancer physician Dr Carlos Barrios, Director of the Latin American Clinical Oncology Research Group from Brazil. Produced by: Fiona Hill and Maria Simons Studio Engineer: Bob Nettles

Sarah Fortune is a Professor of Immunology and Infectious Diseases at the Harvard T.H Chan School of Public Health and Director of the TB Research Program at the Ragon Institute of MGH, Harvard and MIT. We discuss her research into the interactions between Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) and its human hosts. Specifically, we explore some approaches to explain the variability in infection and treatment outcomes, as Mtb infection remains asymptomatic in 90-95% of individuals but causes severe disease in others. We discuss How bacterial and hosts determinants contribute to variability of outcomes A genome-wide strategy using CRISPR to identify target genes influencing the response to mycobacterial infection in macrophages The emerging roles of antibodies in the protection against TB disease The potential of technology-driven science in pushing the TB field forward Prof Sarah Fortune's lab page: https://sites.sph.harvard.edu/fortune-lab/ Link to the genome-wide screening of host:mycobacterial interactions discussed ( Open Access): https://pubmed.ncbi.nlm.nih.gov/32970993/ STOP TB Partnership : http://www.stoptb.org

Badan Kesehatan Dunia menyatakan setiap tahun 10 juta penduduk dunia jatuh sakit akibat Tuberkulosis (TBC) dan penyebaran penyakit ini dapat meluas di tengah pandemi COVID-19. Stop TB Partnership (global) mengindikasikan jumlah orang dengan TBC pada 2025 akan bertambah 6 jutaan dan kematian akibat TBC bertambah lebih dari sejuta di dunia. Sementar itu, pada tahun 2020 Indonesia masuk dalam tiga negara dengan beban tuberkulosis (TBC) terbesar di dunia. Lalu bagaimana upaya pengendalian TB di tengah pandemi ini? Apa saja tantangannya? untuk mengetahui penjelasannya, kita akan simak penjelasan Program Manager Principal Recipient TB Aisyiyah, Tuti Alawiyah dan Pokja Infeksi Perhimpunan Dokter Paru Indonesia (PDPI), Dokter Erlina Burhan. *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Deccan Herald's Pandemic Podcast focuses on the COVID-19 situation. In this episode, DH journalist Varsha Gowda talks to Deputy Executive Director of Stop TB Partnership, Dr Suvanand Sahu on how COVID-19 can affect tuberculosis patients. For latest news and updates, log on to www.deccanherald.com Check out our e-paper www.deccanheraldepaper.com To read news on the go, sign up to our Telegram channel t.me/deccanheraldnews

Ira Pastor, ideaXme exponential health ambassador, interviews Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership,a partnership whose activities focus chiefly on raising awareness about TB and advocating for greater commitment to, and funding for, TB prevention, treatment and research. Tuberculosis: Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those affected. TB is one of the top 10 causes of death and the leading cause of death from a single infectious agent (above HIV/AIDS). As of 2018 one-quarter of the world's population is thought to be infected with TB. New infections occur in about 1% of the population each year. In 2017, there were more than 10 million cases of active TB which resulted in 1.6 million deaths. More than 95% of deaths occurred in developing countries, and more than 50% in India, China, Indonesia, Pakistan, and the Philippines. Tuberculosis prevention and control efforts rely primarily on the vaccination of infants and the detection and appropriate treatment of active cases, which involves combinations of several antibiotics to reduce the risk of the bacteria developing antibiotic resistance. The main vaccine is the Bacillus Calmette-Guérin (BCG) vaccine. In children it decreases the risk of getting the infection by 20% and the risk of infection turning into active disease by nearly 60%. BCG is the most widely used vaccine worldwide, with more than 90% of all children being vaccinated. The immunity it induces decreases after about ten years. A number of new vaccines are in development. The World Health Organization (WHO) declared TB a "global health emergency." Dr. Lucica Ditiu: Dr. Lucica Ditiu is the Executive Director of the Stop TB Partnership, a partnership whose activities focus chiefly on raising awareness about TB and advocating for greater commitment to, and funding for, TB prevention, treatment and research. Its 1,500 partner organizations include international, nongovernmental and governmental organizations and patient groups. The secretariat is based in Geneva, Switzerland and is administered by The United Nations Office for Project Services (UNOPS), an operational arm of the United Nations. Dr. Ditiu is a physician and public health expert who has devoted her career to helping and supporting people affected by TB, especially those most vulnerable, most stigmatized and living in impoverished communities. Dr. Ditiu is a specialist in lung diseases and began practicing medicine in 1992 in Romania. She started her international career with the WHO in January 2000 as a medical officer for TB in Albania, Kosovo and Macedonia, within the disaster and preparedness unit. She has worked for the past 18 years in the WHO and UN system at every level: national, sub-regional, regional and global. Dr. Ditiu has led the Stop TB Partnership (StopTB) for the last 8 years. Under her leadership, the organization has gained a clear identity and evolved into a lean, innovative and progressive team that represents one of the most influential advocacy voices on global health and tuberculosis, providing support, financial as well as TB medicines and diagnostics, for a TB response towards a world without TB. On this episode we will hear from Dr. Ditiu: About her background; how she developed an interest in science, medicine, pulmonology, and in the public health problem that is TB. The current state of the TB therapeutic and prevention landscape in 2019. Why we are still using vaccines and antibiotic "cocktails" that are many decades old. Why does TB seems like an issue that has taken a bit of a "back seat" to HIV and malaria research? An overview of StopTB. Future research and clinical visions related to TB, such as areas she is most excited about as well as areas of concerns. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview on how the UK Government is trying to add 5 healthy years to citizen's lives! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including oniTunes,SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, Google Podcasts, YouTube, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

Join us, with special guests Nora Rodriguez, a TB patient and advocate, and David Bryden, RESULTS TB Officer for a conversation about the impact of tuberculosis and the importance of advocating for an end to TB around the world.Webinar recording can be found here.Slides can be downloaded here.Webinar transcript is here. This podcast is dedicated to the memory of Nora Rodriguez, who passed away on March 26, 2016. A tribute to Nora from the Stop TB Partnership can be found here. 

Read the full article with photos at  https://www.otsuka.co.jp/en/company/globalnews/detail.php?id=226&date=2016-04-19   Otsuka and the Stop TB Partnership’s Global Drug Facility (GDF) announced a worldwide access plan for delamanid, one of only two medications approved to treat multidrug-resistant tuberculosis (MDR-TB) in the last 40 years. The GDF is the largest supplier of quality assured TB treatments in the public sector, which gives it a unique position to catalyse uptake and expedite access to patients living in countries where TB medications are urgently needed. Launched in 2001 by the World Health Organization (WHO), the GDF was created out of a need to build an efficient system of procurement and distribution of high-quality TB drugs. Apart from procurement, the GDF provides a unique package of services, including technical assistance in TB treatment management and monitoring of TB drug use. This innovative partnership with Otsuka opens access to over 100 low- and middle-income countries that are eligible for financing through the Global Fund to Fight AIDS, TB and Malaria and that follow WHO guidelines for the proper management of MDR-TB. As part of this partnership, GDF will also include delamanid in their Strategic Rotating Stockpile to ensure treatments get to people in need as quickly as possible. Apart from establishing a formalized partnership that ensures the supply of delamanid, Otsuka and GDF will work together to support communities with education, training, technical assistance, and TB advocacy activities. Access to a reliable supply of high quality drugs is of great importance, as patients can develop TB drug resistance as a result of poor quality drugs and unreliable supply channels. Widespread drug resistance complicates and lengthens treatment, and as the disease is airborne just like other types of TB, it poses a major public health risk. Nearly half a million people each year develop MDR-TB and of those diagnosed and enrolled in treatment, only 50% are successfully treated. This partnership is a key component of Otsuka’s wider strategy called the “FightTBack” initiative to scale up programmatic use of delamanid and fight TB through innovative R&D, ensuring responsible access to patients, optimizing patient management, and collaborative capacity building. In line with its philosophy of addressing unmet medical needs, Otsuka is currently testing the first-ever pediatric MDR-TB formulation. Otsuka is continuing its research into innovative ways to fight TB, including development of mobile health technology for patients to receive treatment reminders on their smart phones and involvement in multiple research partnerships looking at shorter, more efficient and more patient-friendly ways to fight MDR-TB.

Dr Lucica Ditiu is the Executive Secretary of the Stop TB Partnership, a global partnership of more than 1300 partners – ranging from multilaterals to community- and faith-based organisations – with a vision of ending tuberculosis (TB), hosted by UNOPS in Geneva. Camilla Burkot caught up with her during her recent visit to Canberra to talk about funding for TB research, engaging politicians, and what the Stop TB Partnership is doing to combat TB stigma. Download the transcript here: http://devpolicy.org/pdf/blog/Transcript_interview-with-Lucica-Ditiu-2Sept2015.pdf

If you experience any technical difficulties with this video or would like to make an accessibility-related request, please send a message to digicomm@uchicago.edu. Earlier this year, the University of Chicago Alumni Association recognized Chicago Harris alumnus Sandeep Ahuja, MPP’06, for his efforts to address the global pandemic of tuberculosis. Ahuja cofounded Operation ASHA, a nonprofit that provides services to more than 6 million people. OpASHA, which uses methods involving community-based centers and innovative tracking of patients, was named a model program by the Stop TB Partnership, a World Health Organization affiliate.

Host: Matt Birnholz, MD The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995. In spite of these successes, TB still remains a serious threat, especially for those infected with HIV. HIV is the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB. This special session of Public Health Grand Rounds shed light on myths and misconceptions about TB and HIV, and discussed actions needed in preventing deaths from this lethal combination. This is Part 3 of a lecture in three parts. Part 1 >> Part …

Host: Matt Birnholz, MD The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995. But in spite of these successes, TB still remains a serious threat, especially for those infected with HIV— the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB. This special session of Public Health Grand Rounds sheds light on myths and misconceptions about TB and HIV, and discusses actions needed in preventing deaths from this lethal combination. This is Part 2 of a lecture in three parts. Part 1 >> Part …

Host: Matt Birnholz, MD The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rates have fallen by 35% since 1990, and as many as 6 million lives have been saved since 1995. In spite of these successes, TB still remains a serious threat, especially for those infected with HIV. HIV is the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Among the 1.7 million lives that TB claimed in 2009, 380,000 were among people with HIV infection. While people with HIV who have TB can be effectively diagnosed and treated, more effort is needed to diagnose and treat TB promptly and effectively, and to scale-up preventive treatment for TB. This special session of Public Health Grand Rounds shed light on myths and misconceptions about TB and HIV, and discussed actions needed in preventing deaths from this lethal combination. This is Part 1 of a lecture in three parts. Part 2 >> Part …